ICDs monitoring intrathoracic fluid identify patients at a high risk for
subsequent adverse events in heart failure patients
TORONTO, Sept. 24 /CNW/ -- Today a clinical trial "PARTNERS HF:
Multi-Site Program to Access and Review Trending Information and Evaluate
Correlation to Symptoms in Patients with Heart Failure," was presented at the
12th Annual Scientific Meeting of the Heart Failure Society of America (HFSA)
by Dr. David Whellan, who is an Associate Professor of Medicine, Jefferson
Heart Institute, Thomas Jefferson University, Philadelphia, PA. This clinical
trial highlighted the results of evaluating the intrathoracic fluid data
collected by implantable devices used to treat patients with heart failure as
a possible tool to determine subsequent heart failure related adverse events.
The scientific meeting began Monday at the Metro Toronto Convention Center in
Toronto, Ontario, Canada, and also featured new research, advances in
treatment, guidelines for care, debates, and late breaking clinical trials.
"This finding could be important to help us better understand how body
functions (i.e., excess fluid) effect the progression of heart failure," said
Dr. Barry Greenberg, HFSA President, and Professor of Medicine, and Director,
Advanced Heart Failure Treatment Program, University of California, San Diego.
"Diagnostic measures that would lead to early detection of changes in various
parameters could ultimately allow us to intervene at an early time and thus
prevent cardiac events from occurring."
This trial enrolled 1,000 patients and followed them for a period of 12
months in order to determine the outcome of diagnostic information obtained
from an implantable cardiac defibrillator which measures changes in fluid
levels in the thoracic cavity. Low electrical pulses travel across the thorax
to measure the level of resistance, changes indicate increasing or decreasing
fluid levels. Worsening heart failure is commonly characterized by fluid
accumulation. This study examined whether certain changes in the fluid index
could identify patients at risk for subsequent heart failure event.
Additionally, if a potentially life-threatening arrhythmia is detected, the
devices in this study were capable of delivering an electrical pulse or shock
to correct it.
Dr. Whellan explained that the trial observed how well the diagnostic
parameters predicted the incidence of clinical events. "We now have this
continuous diagnostic data available for patients during in-clinic visits as
well as a remote follow up over the internet. This trial found that patients
with a high intrathoric fluid were about three times more likely to have a
subsequent heart failure event, independent of other clinical variables."
For a complete list of annual meeting sessions or for details on
attending the conference, call (617) 226-7198 or visit www.hfsa.org and click
on Annual Scientific Meeting. There is no registration fee for accredited
journalists. Interview areas will be available on-site in addition to a
fully-staffed press room with phone and internet accessibility.
About Heart Failure
Heart failure is a progressive condition in which the heart muscle
becomes weakened after it is injured from heart attack or high blood pressure
and gradually loses its ability to pump enough blood to supply the body's
needs. Many people are not aware they have heart failure because the symptoms
are often mistaken for signs of getting older. Heart failure affects from 4.6
to 4.8 million individuals in the United States. Demographic and clinical
evidence strongly suggest the prevalence of heart failure will increase
throughout the next decade. Ten to 15 years ago heart failure was considered
a "death sentence;" however, recent advances in treatment have shown that
early diagnosis and proper care in early stages of the condition are key to
slowing, stopping or in some cases reversing progression, improving quality of
life, and extending life expectancy. For more information on heart failure,
please visit www.abouthf.org .
About the Heart Failure Society of America
The Heart Failure Society of America (HFSA) is a nonprofit educational
organization, founded in 1994 as the first organized association of heart
failure experts. Today HFSA has over 1,700 members and provides a forum for
all those interested in heart function, heart failure research and patient
care. The Society also serves as a resource for governmental agencies (FDA,
NIH, NHLBI, CMS). The HFSA Annual Scientific Meeting is designed to highlight
recent advances in the development of strategies to address the complex
epidemiological, clinical and therapeutic issues of heart failure. Additional
information on HFSA can be found at www.hfsa.org .
For further information:
For further information: Kaitlyn Siner, +1-617-226-7192 office,
+1-401-339-0954 cell, firstname.lastname@example.org, or Ben Hendricks,
+1-617-226-7183 office, +1-919-522-2978 cell, email@example.com,
both for The Heart Failure Society of America Web Site: http://www.hfsa.org